Drug-induced cooling may reduce stroke brain damage

Drug cooling revives an old stroke idea with a new delivery method

A long-running idea in stroke medicine is simple to describe and hard to execute: cool the body quickly enough after a stroke to protect threatened brain tissue until blood flow can be restored. The logic is strong. When a clot cuts off circulation, neurons are suddenly starved of oxygen and glucose. Lowering the brain’s energy demand could buy time, limiting the cascade of injury that turns a brief interruption into permanent disability.

What has repeatedly slowed that approach is not the theory but the method. Physical cooling strategies such as blankets, helmets and ice packs have struggled in practice because the body resists being cooled. Patients shiver, become uncomfortable, and often fail to reach or sustain a temperature low enough to make a meaningful difference. That has left therapeutic cooling in an awkward position: biologically appealing, but operationally difficult.

A report highlighted by New Scientist points to a different route. Instead of relying on external devices, researchers tested a drug combination designed to lower core body temperature from inside the body. In animal studies, the approach reduced brain damage after induced stroke. The team has also carried out a preliminary human trial, with a larger follow-up study now positioned as the next step.

Two familiar drugs, used for an unfamiliar purpose

The treatment pairs promethazine and chlorpromazine, two drugs that have been known since the 1950s to reduce body temperature. In the new work, researchers led by Shuaili Xu at Capital Medical University in Beijing administered the combination after induced strokes in mice and rhesus monkeys. According to the supplied source text, the drugs lowered core body temperature, suppressed glucose metabolism in cells and reduced the extent of stroke-related brain damage in both animal models.

That metabolic effect matters because a stroke creates an immediate energy crisis in the brain. If cells can be pushed into a lower-demand state, they may remain viable for longer while clinicians work to reopen blocked vessels. In the monkey experiments, the reported reduction in tissue injury also corresponded with better limb use, suggesting the treatment’s benefits were not limited to scans or laboratory measurements.

The concept resembles a temporary, hibernation-like slowdown. That framing has appeared before in stroke research, but the new study’s significance lies in using drugs to trigger the effect rather than equipment that cools from the outside. If that works reliably, it could help solve one of the field’s biggest implementation problems.

Why physical cooling has disappointed

External cooling has been investigated for decades, and the reason for the repeated interest is obvious: the brain consumes enormous amounts of energy, and even a modest drop in temperature can reduce that demand. But the human body is built to defend its temperature. Cooling blankets and similar systems may seem straightforward, yet they can provoke intense shivering and discomfort, which in turn makes temperature control harder.

In comments summarized by New Scientist, Kirsten Coupland of the University of Newcastle in Australia said physical cooling has not proved feasible for stroke, precisely because the body fights the induction of hypothermia. That assessment captures the practical barrier. A therapy can make biological sense and still fail if patients cannot tolerate it or if hospitals cannot deliver it fast enough and consistently enough in emergency settings.

Drug-induced cooling changes the engineering problem. Rather than forcing the body into hypothermia from the outside, it attempts to shift the body’s internal set of responses. That does not make the therapy proven, but it does make the broader cooling strategy newly plausible.

What happened in people

The researchers did not stop at animal data. The source text says the team conducted a clinical trial involving 32 people who had just had a stroke. Participants received either the promethazine-chlorpromazine combination or a placebo on hospital admission, in addition to standard clot-removal therapy.

That detail is important because it places the drugs in a realistic treatment pathway rather than as a replacement for established care. Modern stroke treatment already depends heavily on speed, especially when doctors can remove a clot mechanically. A protective therapy that fits around that workflow would be far more useful than one that competes with it.

The supplied text does not provide full human efficacy results, so the current evidence should not be overstated. What can be said from the material provided is that the treatment has moved beyond theory and beyond animal-only testing. It has entered early human evaluation, and the investigators plan a follow-up clinical trial.

Why the next trial matters

Stroke medicine is full of approaches that look compelling in preclinical work and then falter in larger studies. That is why the follow-up trial matters more than the novelty of the drug pairing itself. The central questions are practical as much as biological: how quickly can the drugs be given, how much can they safely lower core temperature, which patients benefit most, and whether any cooling benefit translates into better recovery of movement, speech or independence.

There is also the question of timing. Neuroprotection tends to be highly sensitive to how early treatment begins. A therapy that works only in a very short window may still be useful, but only if emergency systems can deliver it without delay. The fact that the study administered treatment upon hospital admission suggests the researchers are already thinking in those operational terms.

Another key issue is whether metabolic suppression can complement reperfusion therapies. Clot removal restores blood flow, but it does not undo all injury, especially when tissue has been deprived for too long. A cooling drug that preserves threatened cells until circulation returns could extend the benefits of existing stroke interventions rather than compete with them.

A cautious but meaningful signal

At this stage, the work is best read as a meaningful signal, not a clinical turning point. The animal results are notable because they span mice and rhesus monkeys, and the source text reports both structural and functional benefit. The early human trial is notable because it indicates the approach can be tested in real patients alongside standard care. But the evidence described here remains preliminary, and major questions about efficacy, safety, treatment window and patient selection remain open.

Even so, the study stands out because it addresses a stubborn translational problem with a pragmatic idea: use known drugs to produce a state that decades of physical cooling devices have struggled to achieve. In stroke care, where minutes matter and brain tissue is lost quickly, therapies that buy even modest amounts of time can have outsized consequences for recovery.

If larger trials confirm the early promise, drug-induced cooling could reopen a chapter of stroke treatment that many clinicians may have viewed as conceptually attractive but clinically frustrating. For now, the main development is this: a once-difficult cooling strategy may have found a more workable delivery system, and that alone is enough to justify close attention as the next trial gets underway.

This article is based on reporting by New Scientist. Read the original article.